Navigation Links
CryoCor Appoints New Vice President of Sales and Marketing
Date:11/2/2007

SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq: CRYO), a medical device company focused on the treatment of cardiac arrhythmias, announced today the appointment of Mark Adams as Vice President of Sales and Marketing. Mr. Adams brings to CryoCor over 20 years of cardiac related medical device sales and marketing experience. He will be responsible for leading CryoCor's commercialization efforts for its Cardiac Cryoablation System, which was approved by the FDA in August 2007 for the treatment of right atrial flutter. CryoCor recently announced the completion of enrollment in its pivotal trial for the treatment of atrial fibrillation, the first company to complete enrollment in a randomized pivotal trial.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor, said, "I am happy to welcome Mark to CryoCor. Throughout his career, Mark has successfully built and managed sales and marketing teams that have consistently exceeded expectations. We believe that his proven track record, combined with a deep understanding of the cardiac and electrophysiology device markets, will make major contributions as we look to the acceleration of our commercialization efforts and drive adoption of our Cryoablation System. Mark has developed important relationships in the field of electrophysiology that we believe will immediately benefit CryoCor's commercial plans."

Mark Adams, Vice President of Sales and Marketing, commented "I look forward to leading the commercialization efforts for our Cardiac Cryoablation System. I believe this is an important product that meets a significant need in the medical community for the treatment of right atrial flutter and atrial fibrillation. My discussions with physicians have confirmed the thesis that Cryoablation is important in the treatment of these diseases and I look forward to the opportunity to promote and commercialize this product."

Mr. Adams has served at the management and executive levels with several leading electrophysiology companies, including EP Technologies (prior to its acquisition by Boston Scientific), Irvine Biomedical (prior to its acquisition by St. Jude Medical), EP Medsystems and Instromedics, a leader in cardiac event monitoring. Throughout his career, Mr. Adams has been involved in a number of strategic alliance relationships, including with Boston Scientific, Guidant, Medtronic, Phillips and St. Jude Medical. Prior to joining CryoCor, Mr. Adams served as a business consultant providing sales, marketing, operational and staffing expertise to a range of organizations primarily in the medical device industry. Mr. Adams has a long track record of successfully implemented strategic sales and marketing plans.

About CryoCor

CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary Cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, or the Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The Cryoablation System has been approved in Europe for the treatment of all supraventricular tachycardias, including atrial fibrillation and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor has completed enrollment in a pivotal trial to evaluate the safety and efficacy of the Cryoablation System for the treatment of atrial fibrillation and the Cryoablation System has been approved in the United States for the treatment of right atrial flutter. For more information please visit the Company's website at http://www.cryocor.com.

Forward Looking Statements

The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to the pace and success of CryoCor's commercialization activities, Mr. Adams' ability to contribute to those activities, and the potential benefits of and prospects for market adoption of CryoCor's Cardiac Cryoablation System, all of which are prospective. Such statements are only predictions and reflect CryoCor's expectations and assumptions as of the date of this press release based on currently available operating, financial and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks associated with the Company's ability to successfully commercialize its Cryoablation System in the United States and else; risks involved with CryoCor's ability to obtain regulatory approval in the United States for its Cryoablation System for use in treating atrial fibrillation; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; risks associated with the Company's ability to maintain and achieve milestones under collaborative agreements and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.

Contact:

CryoCor, Inc. The Ruth Group

Gregory J. Tibbitts Nick Laudico / Zack Kubow (investors)

Chief Financial Officer (646) 536-7030 / 7020

(858) 909-2200 nlaudico@theruthgroup.com

gtibbitts@cryocor.com zkubow@theruthgroup.com

Jason Rando (media)

(646) 536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE CryoCor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clintons new problem - Is the outgoing American president suffering from skin cancer?
2. Past President Narayanans Condition Still Critical
3. President and Founder of National Obesity Forum Resigns
4. President Bush Urges Citizens to Invest In Health Savings Account (HSAs)
5. President Bush proposes HSAs scheme for the benefit of both the workers and the country
6. President’s verdict: no need to panic over bird fl
7. Delhi Hospitals On Standby For President Bush
8. Former IMO President Shows Interest In Winning General Election
9. Chicken Dishes Were Off The Menu At Pakistan Presidents House
10. Man Appeals to President to Save His Ailing Son
11. President Kalam Meets Striking Medicos However Stir to Continue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... set up in 2006 as a non-profit organization to unite pharmaceutical and healthcare ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. ... advocates for the mass media launching of story movements to highlight what's most ... their unfortunate experiences; such a movement can generate the network power to improve ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated ... it is one of the early adopters completing EU-U.S. Privacy Shield Certification from the ... provide companies on both sides of the Atlantic with a mechanism to comply with ...
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift is ... by smoothing and tightening the skin of the face to create more youthful ... aging with very little downtime, Silhouette Instalift is a novel, minimally invasive facial ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- A Small Business Innovative Research (SBIR) grant has ... to Phoenix -based NeuroEM Therapeutics, Inc. ... will seek to determine an optimal set of treatment ... to treat Alzheimer,s Disease. The grant will also investigate ... other neurologic disorders such as Parkinson,s Disease and PTSD. ...
(Date:12/8/2016)... in the United States will continue in 2017, say ... December 2016 Semiannual Economic Forecast. Expectations are for a ... as indicated in the monthly ISM ® ... is optimistic about growth in 2017, with revenues expected ... sector indicates that 14 of its industries will see ...
(Date:12/8/2016)...  Hanson Research, an innovative leader in the ... testing instruments for the pharmaceutical industry, announced today ... ("Teledyne"). The move is designed to deepen investments ... as well as expand resources for further market ... services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
Breaking Medicine Technology: